HOME | SynapCell

clinically-relevant biomarkers
in vivo. predictive.
Learn how it works >>

SynapCell is a preclinical stage biotechnology company
focused on Central Nervous System (CNS) disorders

Epilepsy
Programs
AED efficacy evaluation
using predictive EEG biomarkers and models of epilepsy
Cognitive
Programs
Accurate identification
of defects in information processing
Movement
Programs
Non behavior-related measures
of motor dysfunction within the brain

STOP GUESSING

We reveal the therapeutic potential
of pharmaceutical compounds in vivo following clinical protocols.
Since 2005, our predictive decision-making assays help our clients worldwide
clear their path to clinical success.



News & Events

BioJapan 2018, Yokohama

Yokohama, Japan | OCT 10-12, 2018

SFN 2018 - Major milestones achieved

San Diego, CA | Nov 4-7 2018

Our New Brochure is out!

SAINT ISMIER, FRANCE | MAY 18 2018

BIO2018, Boston

BOSTON, MA | June 4-7 2018

Meet SynapCell at EILAT XIV

Madrid, Spain | MAY 13-16 2018

SynapCell et NeuroService lancent une offre commune

Saint Ismier, France | MARCH 21 2018

Les nouvelles perspectives de SynapCell

Saint Ismier, France | MARCH 19 2018

Today is the International Epilepsy Day

Grenoble, France | FEB 12 2018

NeurOsyn. Unveiled.

Washington, D.C | Nov 15 2017